C
Novartis AG
NVS
$111.88
$0.460.41%
C
Hold
1/31/2025Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 1/31/2025 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 33.3% from $6.29B to $4.19B, earnings per share declined from $1.57 to $1.4118, and EBIT declined 7.94% from $4.41B to $4.06B.
Novartis AG (NVS) was downgraded to C+ from B- on 1/31/2025 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 33.3% from $6.29B to $4.19B, earnings per share declined from $1.57 to $1.4118, and EBIT declined 7.94% from $4.41B to $4.06B.
B
Buy
12/10/2024Downgrade
Novartis AG (NVS) was downgraded to B- from B on 12/10/2024 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from $1.59 to $1.57.
Novartis AG (NVS) was downgraded to B- from B on 12/10/2024 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from $1.59 to $1.57.
B
Buy
9/6/2024Downgrade
Novartis AG (NVS) was downgraded to B from B+ on 9/6/2024 due to a decline in the valuation index and volatility index.
Novartis AG (NVS) was downgraded to B from B+ on 9/6/2024 due to a decline in the valuation index and volatility index.
B
Buy
8/22/2024Upgraded
Novartis AG (NVS) was upgraded to B+ from B on 8/22/2024 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 115.23% from $2.27B to $4.88B, earnings per share increased from $1.31 to $1.59, and EBIT increased 15.28% from $3.73B to $4.3B.
Novartis AG (NVS) was upgraded to B+ from B on 8/22/2024 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 115.23% from $2.27B to $4.88B, earnings per share increased from $1.31 to $1.59, and EBIT increased 15.28% from $3.73B to $4.3B.
B
Buy
6/25/2024Upgraded
Novartis AG (NVS) was upgraded to B from B- on 6/25/2024 due to an increase in the volatility index.
Novartis AG (NVS) was upgraded to B from B- on 6/25/2024 due to an increase in the volatility index.
B
Buy
4/25/2024Downgrade
Novartis AG (NVS) was downgraded to B- from B on 4/25/2024 due to a decline in the dividend index, growth index and total return index. Earnings per share declined from $4.1074 to $1.31, and operating cash flow declined 29.11% from $3.2B to $2.27B.
Novartis AG (NVS) was downgraded to B- from B on 4/25/2024 due to a decline in the dividend index, growth index and total return index. Earnings per share declined from $4.1074 to $1.31, and operating cash flow declined 29.11% from $3.2B to $2.27B.
B
Buy
2/1/2024Upgraded
Novartis AG (NVS) was upgraded to B from C+ on 2/1/2024 due to a substantial increase in the valuation index, growth index and dividend index. Earnings per share increased from $0.8505 to $4.0896.
Novartis AG (NVS) was upgraded to B from C+ on 2/1/2024 due to a substantial increase in the valuation index, growth index and dividend index. Earnings per share increased from $0.8505 to $4.0896.
C
Hold
11/1/2023Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 11/1/2023 due to a large decline in the growth index, solvency index and total return index. The quick ratio declined from 0.65 to 0.41, earnings per share declined from $1.1066 to $0.8505, and debt to equity increased from 0.52 to 0.62.
Novartis AG (NVS) was downgraded to C+ from B- on 11/1/2023 due to a large decline in the growth index, solvency index and total return index. The quick ratio declined from 0.65 to 0.41, earnings per share declined from $1.1066 to $0.8505, and debt to equity increased from 0.52 to 0.62.
B
Buy
8/4/2023Downgrade
Novartis AG (NVS) was downgraded to B- from B on 8/4/2023 due to a decline in the growth index, efficiency index and valuation index.
Novartis AG (NVS) was downgraded to B- from B on 8/4/2023 due to a decline in the growth index, efficiency index and valuation index.
B
Buy
7/20/2023Upgraded
Novartis AG (NVS) was upgraded to B from C+ on 7/20/2023 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 20.93% from $2.96B to $3.58B, EBIT increased 10.95% from $3.33B to $3.7B, and total revenue increased 5.51% from $13.21B to $13.94B.
Novartis AG (NVS) was upgraded to B from C+ on 7/20/2023 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 20.93% from $2.96B to $3.58B, EBIT increased 10.95% from $3.33B to $3.7B, and total revenue increased 5.51% from $13.21B to $13.94B.
C
Hold
3/24/2023Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 3/24/2023 due to an increase in the volatility index and valuation index.
Novartis AG (NVS) was upgraded to C+ from C on 3/24/2023 due to an increase in the volatility index and valuation index.
C
Hold
3/8/2023Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 3/8/2023 due to a decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to C from C+ on 3/8/2023 due to a decline in the volatility index and total return index.
C
Hold
2/21/2023Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 2/21/2023 due to an increase in the volatility index and valuation index.
Novartis AG (NVS) was upgraded to C+ from C on 2/21/2023 due to an increase in the volatility index and valuation index.
C
Hold
2/3/2023Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 2/3/2023 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 12.92% from $4.72B to $4.11B, EBIT declined 7.82% from $3.33B to $3.07B, and earnings per share declined from $0.72 to $0.6861.
Novartis AG (NVS) was downgraded to C from C+ on 2/3/2023 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 12.92% from $4.72B to $4.11B, EBIT declined 7.82% from $3.33B to $3.07B, and earnings per share declined from $0.72 to $0.6861.
C
Hold
2/1/2023Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 2/1/2023 due to a noticeable decline in the growth index, total return index and valuation index. Earnings per share declined from $0.77 to $0.72, and total revenue declined 1.86% from $13.09B to $12.84B.
Novartis AG (NVS) was downgraded to C+ from B- on 2/1/2023 due to a noticeable decline in the growth index, total return index and valuation index. Earnings per share declined from $0.77 to $0.72, and total revenue declined 1.86% from $13.09B to $12.84B.
B
Buy
1/25/2023Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 1/25/2023 due to an increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to B- from C+ on 1/25/2023 due to an increase in the total return index and volatility index.
C
Hold
1/13/2023Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 1/13/2023 due to a noticeable increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to C+ from C on 1/13/2023 due to a noticeable increase in the total return index and volatility index.
C
Hold
11/4/2022Upgraded
Novartis AG (NVS) was upgraded to C from C- on 11/4/2022 due to an increase in the growth index and volatility index.
Novartis AG (NVS) was upgraded to C from C- on 11/4/2022 due to an increase in the growth index and volatility index.
C
Hold
10/20/2022Downgrade
Novartis AG (NVS) was downgraded to C- from C on 10/20/2022 due to a noticeable decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to C- from C on 10/20/2022 due to a noticeable decline in the volatility index and total return index.
C
Hold
7/20/2022Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 7/20/2022 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 23.76% from $2.22B to $1.69B.
Novartis AG (NVS) was downgraded to C from C+ on 7/20/2022 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 23.76% from $2.22B to $1.69B.
C
Hold
7/19/2022Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 7/19/2022 due to an increase in the volatility index.
Novartis AG (NVS) was upgraded to C+ from C on 7/19/2022 due to an increase in the volatility index.
C
Hold
6/30/2022Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 6/30/2022 due to a noticeable decline in the total return index.
Novartis AG (NVS) was downgraded to C from C+ on 6/30/2022 due to a noticeable decline in the total return index.
C
Hold
6/8/2022Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 6/8/2022 due to a decline in the volatility index and valuation index.
Novartis AG (NVS) was downgraded to C+ from B- on 6/8/2022 due to a decline in the volatility index and valuation index.
B
Buy
5/24/2022Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 5/24/2022 due to an increase in the total return index.
Novartis AG (NVS) was upgraded to B- from C+ on 5/24/2022 due to an increase in the total return index.
C
Hold
5/16/2022Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 5/16/2022 due to an increase in the total return index, valuation index and growth index.
Novartis AG (NVS) was upgraded to C+ from C on 5/16/2022 due to an increase in the total return index, valuation index and growth index.
C
Hold
4/29/2022Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 4/29/2022 due to a decline in the volatility index.
Novartis AG (NVS) was downgraded to C from C+ on 4/29/2022 due to a decline in the volatility index.
C
Hold
4/28/2022Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 4/28/2022 due to a decline in the volatility index, dividend index and growth index. Earnings per share declined from $7.2409 to $0.99, operating cash flow declined 57.54% from $3.88B to $1.65B, and total revenue declined 5.24% from $13.52B to $12.81B.
Novartis AG (NVS) was downgraded to C+ from B- on 4/28/2022 due to a decline in the volatility index, dividend index and growth index. Earnings per share declined from $7.2409 to $0.99, operating cash flow declined 57.54% from $3.88B to $1.65B, and total revenue declined 5.24% from $13.52B to $12.81B.
B
Buy
4/18/2022Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 4/18/2022 due to a noticeable increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to B- from C+ on 4/18/2022 due to a noticeable increase in the volatility index and total return index.
C
Hold
3/30/2022Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 3/30/2022 due to an increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to C+ from C on 3/30/2022 due to an increase in the volatility index and total return index.
C
Hold
3/4/2022Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 3/4/2022 due to a decline in the volatility index.
Novartis AG (NVS) was downgraded to C from C+ on 3/4/2022 due to a decline in the volatility index.
C
Hold
2/7/2022Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 2/7/2022 due to a major increase in the valuation index, growth index and volatility index. Earnings per share increased from $1.22 to $7.2409, and total revenue increased 1.16% from $13.37B to $13.52B.
Novartis AG (NVS) was upgraded to C+ from C on 2/7/2022 due to a major increase in the valuation index, growth index and volatility index. Earnings per share increased from $1.22 to $7.2409, and total revenue increased 1.16% from $13.37B to $13.52B.
C
Hold
11/3/2021Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 11/3/2021 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from $1.28 to $1.22.
Novartis AG (NVS) was downgraded to C from C+ on 11/3/2021 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from $1.28 to $1.22.
C
Hold
9/23/2021Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 9/23/2021 due to a decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to C+ from B- on 9/23/2021 due to a decline in the volatility index and total return index.
B
Buy
9/10/2021Downgrade
Novartis AG (NVS) was downgraded to B- from B on 9/10/2021 due to a decline in the total return index and volatility index.
Novartis AG (NVS) was downgraded to B- from B on 9/10/2021 due to a decline in the total return index and volatility index.
B
Buy
8/3/2021Upgraded
Novartis AG (NVS) was upgraded to B from B- on 8/3/2021 due to an increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to B from B- on 8/3/2021 due to an increase in the volatility index and total return index.
B
Buy
7/23/2021Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 7/23/2021 due to a significant increase in the growth index, valuation index and total return index. Operating cash flow increased 93.99% from $2.13B to $4.13B, earnings per share increased from $0.91 to $1.28, and EBIT increased 13.28% from $3B to $3.4B.
Novartis AG (NVS) was upgraded to B- from C+ on 7/23/2021 due to a significant increase in the growth index, valuation index and total return index. Operating cash flow increased 93.99% from $2.13B to $4.13B, earnings per share increased from $0.91 to $1.28, and EBIT increased 13.28% from $3B to $3.4B.
C
Hold
6/17/2021Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 6/17/2021 due to an increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to C+ from C on 6/17/2021 due to an increase in the total return index and volatility index.
C
Hold
5/3/2021Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 5/3/2021 due to a decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to C from C+ on 5/3/2021 due to a decline in the volatility index and total return index.
C
Hold
4/28/2021Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 4/28/2021 due to a significant decline in the growth index, dividend index and solvency index. Operating cash flow declined 46.82% from $4.01B to $2.13B, the quick ratio declined from 0.65 to 0.41, and debt to equity increased from 0.64 to 0.72.
Novartis AG (NVS) was downgraded to C+ from B- on 4/28/2021 due to a significant decline in the growth index, dividend index and solvency index. Operating cash flow declined 46.82% from $4.01B to $2.13B, the quick ratio declined from 0.65 to 0.41, and debt to equity increased from 0.64 to 0.72.
B
Buy
4/22/2021Downgrade
Novartis AG (NVS) was downgraded to B- from B on 4/22/2021 due to a decline in the volatility index and valuation index.
Novartis AG (NVS) was downgraded to B- from B on 4/22/2021 due to a decline in the volatility index and valuation index.
B
Buy
4/7/2021Upgraded
Novartis AG (NVS) was upgraded to B from B- on 4/7/2021 due to an increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to B from B- on 4/7/2021 due to an increase in the volatility index and total return index.
B
Buy
3/23/2021Downgrade
Novartis AG (NVS) was downgraded to B- from B on 3/23/2021 due to a decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to B- from B on 3/23/2021 due to a decline in the volatility index and total return index.
B
Buy
2/19/2021Upgraded
Novartis AG (NVS) was upgraded to B from B- on 2/19/2021 due to an increase in the valuation index, volatility index and growth index.
Novartis AG (NVS) was upgraded to B from B- on 2/19/2021 due to an increase in the valuation index, volatility index and growth index.
B
Buy
1/28/2021Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 1/28/2021 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 26.9% from $3.16B to $4.01B, earnings per share increased from $0.84 to $0.9211, and total revenue increased 2.84% from $12.54B to $12.89B.
Novartis AG (NVS) was upgraded to B- from C+ on 1/28/2021 due to a noticeable increase in the growth index, volatility index and dividend index. Operating cash flow increased 26.9% from $3.16B to $4.01B, earnings per share increased from $0.84 to $0.9211, and total revenue increased 2.84% from $12.54B to $12.89B.
C
Hold
11/19/2020Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 11/19/2020 due to an increase in the growth index, volatility index and valuation index. EBIT increased 10.26% from $2.89B to $3.18B, total revenue increased 7.88% from $11.62B to $12.54B, and earnings per share increased from $0.81 to $0.84.
Novartis AG (NVS) was upgraded to C+ from C on 11/19/2020 due to an increase in the growth index, volatility index and valuation index. EBIT increased 10.26% from $2.89B to $3.18B, total revenue increased 7.88% from $11.62B to $12.54B, and earnings per share increased from $0.81 to $0.84.
C
Hold
7/22/2020Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 7/22/2020 due to a substantial decline in the growth index and valuation index. Earnings per share declined from $0.95 to $0.81, EBIT declined 12.47% from $3.3B to $2.89B, and total revenue declined 8.55% from $12.71B to $11.62B.
Novartis AG (NVS) was downgraded to C from C+ on 7/22/2020 due to a substantial decline in the growth index and valuation index. Earnings per share declined from $0.95 to $0.81, EBIT declined 12.47% from $3.3B to $2.89B, and total revenue declined 8.55% from $12.71B to $11.62B.
C
Hold
7/1/2020Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 7/1/2020 due to an increase in the total return index.
Novartis AG (NVS) was upgraded to C+ from C on 7/1/2020 due to an increase in the total return index.
C
Hold
5/14/2020Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 5/14/2020 due to a decline in the volatility index, total return index and solvency index.
Novartis AG (NVS) was downgraded to C from C+ on 5/14/2020 due to a decline in the volatility index, total return index and solvency index.
C
Hold
4/29/2020Downgrade
Novartis AG (NVS) was downgraded to C+ from B- on 4/29/2020 due to a decline in the dividend index, volatility index and valuation index.
Novartis AG (NVS) was downgraded to C+ from B- on 4/29/2020 due to a decline in the dividend index, volatility index and valuation index.
B
Buy
4/13/2020Downgrade
Novartis AG (NVS) was downgraded to B- from B on 4/13/2020 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from $0.89 to $0.4913, operating cash flow declined 22.4% from $4.56B to $3.54B, and EBIT declined 12.02% from $2.94B to $2.58B.
Novartis AG (NVS) was downgraded to B- from B on 4/13/2020 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from $0.89 to $0.4913, operating cash flow declined 22.4% from $4.56B to $3.54B, and EBIT declined 12.02% from $2.94B to $2.58B.
B
Buy
12/9/2019Upgraded
Novartis AG (NVS) was upgraded to B from B- on 12/9/2019 due to an increase in the volatility index and solvency index.
Novartis AG (NVS) was upgraded to B from B- on 12/9/2019 due to an increase in the volatility index and solvency index.
B
Buy
10/23/2019Downgrade
Novartis AG (NVS) was downgraded to B- from B on 10/23/2019 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $2.9107 to $0.89, EBIT declined 4.33% from $3.07B to $2.94B, and the quick ratio declined from 0.61 to 0.59.
Novartis AG (NVS) was downgraded to B- from B on 10/23/2019 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from $2.9107 to $0.89, EBIT declined 4.33% from $3.07B to $2.94B, and the quick ratio declined from 0.61 to 0.59.
B
Buy
9/17/2019Upgraded
Novartis AG (NVS) was upgraded to B from B- on 9/17/2019 due to an increase in the solvency index, total return index and efficiency index. Net income increased 284.99% from $1.77B to $6.8B, the quick ratio increased from 0.27 to 0.61, and debt to equity declined from 0.61 to 0.55.
Novartis AG (NVS) was upgraded to B from B- on 9/17/2019 due to an increase in the solvency index, total return index and efficiency index. Net income increased 284.99% from $1.77B to $6.8B, the quick ratio increased from 0.27 to 0.61, and debt to equity declined from 0.61 to 0.55.
B
Buy
5/1/2019Downgrade
Novartis AG (NVS) was downgraded to B- from B on 5/1/2019 due to a large decline in the solvency index, total return index and efficiency index. The quick ratio declined from 0.9 to 0.27, debt to equity increased from 0.41 to 0.65, and total capital declined 29.72% from $110.84B to $77.9B.
Novartis AG (NVS) was downgraded to B- from B on 5/1/2019 due to a large decline in the solvency index, total return index and efficiency index. The quick ratio declined from 0.9 to 0.27, debt to equity increased from 0.41 to 0.65, and total capital declined 29.72% from $110.84B to $77.9B.
B
Buy
1/23/2019Upgraded
Novartis AG (NVS) was upgraded to B from B- on 1/23/2019 due to an increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to B from B- on 1/23/2019 due to an increase in the total return index and volatility index.
B
Buy
1/8/2019Downgrade
Novartis AG (NVS) was downgraded to B- from B on 1/8/2019 due to a decline in the total return index.
Novartis AG (NVS) was downgraded to B- from B on 1/8/2019 due to a decline in the total return index.
B
Buy
12/24/2018Upgraded
Novartis AG (NVS) was upgraded to B from B- on 12/24/2018 due to an increase in the volatility index, total return index and valuation index.
Novartis AG (NVS) was upgraded to B from B- on 12/24/2018 due to an increase in the volatility index, total return index and valuation index.
B
Buy
11/6/2018Upgraded
Novartis AG (NVS) was upgraded to B- from C+ on 11/6/2018 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.79 to 0.82, and debt to equity declined from 0.42 to 0.41.
Novartis AG (NVS) was upgraded to B- from C+ on 11/6/2018 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.79 to 0.82, and debt to equity declined from 0.42 to 0.41.
C
Hold
9/25/2018Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 9/25/2018 due to a noticeable increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to C+ from C on 9/25/2018 due to a noticeable increase in the volatility index and total return index.
C
Hold
7/20/2018Upgraded
Novartis AG (NVS) was upgraded to C from C- on 7/20/2018 due to a substantial increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.86 to $3.31, operating cash flow increased 56.8% from $2.51B to $3.94B, and the quick ratio increased from 0.55 to 0.79.
Novartis AG (NVS) was upgraded to C from C- on 7/20/2018 due to a substantial increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.86 to $3.31, operating cash flow increased 56.8% from $2.51B to $3.94B, and the quick ratio increased from 0.55 to 0.79.
C
Hold
7/5/2018Downgrade
Novartis AG (NVS) was downgraded to C- from C on 7/5/2018 due to a large decline in the total return index, dividend index and volatility index.
Novartis AG (NVS) was downgraded to C- from C on 7/5/2018 due to a large decline in the total return index, dividend index and volatility index.
C
Hold
2/12/2018Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 2/12/2018 due to a decline in the volatility index, growth index and solvency index.
Novartis AG (NVS) was downgraded to C from C+ on 2/12/2018 due to a decline in the volatility index, growth index and solvency index.
C
Hold
1/26/2018Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 1/26/2018 due to an increase in the total return index, dividend index and solvency index. The quick ratio increased from 0.7 to 0.86, and debt to equity declined from 0.42 to 0.38.
Novartis AG (NVS) was upgraded to C+ from C on 1/26/2018 due to an increase in the total return index, dividend index and solvency index. The quick ratio increased from 0.7 to 0.86, and debt to equity declined from 0.42 to 0.38.
C
Hold
11/24/2017Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 11/24/2017 due to a decline in the volatility index and valuation index.
Novartis AG (NVS) was downgraded to C from C+ on 11/24/2017 due to a decline in the volatility index and valuation index.
C
Hold
11/9/2017Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 11/9/2017 due to an increase in the growth index, volatility index and valuation index.
Novartis AG (NVS) was upgraded to C+ from C on 11/9/2017 due to an increase in the growth index, volatility index and valuation index.
C
Hold
10/25/2017Downgrade
Novartis AG (NVS) was downgraded to C from C+ on 10/25/2017 due to a noticeable decline in the growth index and efficiency index.
Novartis AG (NVS) was downgraded to C from C+ on 10/25/2017 due to a noticeable decline in the growth index and efficiency index.
C
Hold
10/13/2017Upgraded
Novartis AG (NVS) was upgraded to C+ from C on 10/13/2017 due to a large increase in the volatility index, growth index and total return index. Operating cash flow increased 75.16% from $2.05B to $3.58B, earnings per share increased from $0.7 to $0.83, and EBIT increased 9.67% from $2.14B to $2.35B.
Novartis AG (NVS) was upgraded to C+ from C on 10/13/2017 due to a large increase in the volatility index, growth index and total return index. Operating cash flow increased 75.16% from $2.05B to $3.58B, earnings per share increased from $0.7 to $0.83, and EBIT increased 9.67% from $2.14B to $2.35B.
C
Hold
5/24/2017Upgraded
Novartis AG (NVS) was upgraded to C from C- on 5/24/2017 due to an increase in the total return index, growth index and solvency index. Earnings per share increased from $0.399 to $0.7, and EBIT increased 5.52% from $2.03B to $2.14B.
Novartis AG (NVS) was upgraded to C from C- on 5/24/2017 due to an increase in the total return index, growth index and solvency index. Earnings per share increased from $0.399 to $0.7, and EBIT increased 5.52% from $2.03B to $2.14B.
C
Hold
11/25/2016Downgrade
Novartis AG (NVS) was downgraded to C- from C on 11/25/2016 due to a decline in the total return index, solvency index and volatility index.
Novartis AG (NVS) was downgraded to C- from C on 11/25/2016 due to a decline in the total return index, solvency index and volatility index.
C
Hold
7/11/2016Upgraded
Novartis AG (NVS) was upgraded to C from C- on 7/11/2016 due to an increase in the volatility index and total return index.
Novartis AG (NVS) was upgraded to C from C- on 7/11/2016 due to an increase in the volatility index and total return index.
C
Hold
4/22/2016Downgrade
Novartis AG (NVS) was downgraded to C- from C on 4/22/2016 due to a significant decline in the valuation index, growth index and dividend index. Operating cash flow declined 62.91% from $4.16B to $1.54B, and total revenue declined 7.76% from $12.8B to $11.81B.
Novartis AG (NVS) was downgraded to C- from C on 4/22/2016 due to a significant decline in the valuation index, growth index and dividend index. Operating cash flow declined 62.91% from $4.16B to $1.54B, and total revenue declined 7.76% from $12.8B to $11.81B.
C
Hold
3/11/2016Downgrade
Novartis AG (NVS) was downgraded to C from B- on 3/11/2016 due to a major decline in the volatility index and total return index.
Novartis AG (NVS) was downgraded to C from B- on 3/11/2016 due to a major decline in the volatility index and total return index.
B
Buy
3/8/2016Downgrade
Novartis AG (NVS) was downgraded to B- from B on 3/8/2016 due to a decline in the total return index.
Novartis AG (NVS) was downgraded to B- from B on 3/8/2016 due to a decline in the total return index.
B
Buy
2/2/2016Upgraded
Novartis AG (NVS) was upgraded to B from B- on 2/2/2016 due to an increase in the dividend index, solvency index and valuation index. The quick ratio increased from 0.51 to 0.66, and debt to equity declined from 0.3 to 0.28.
Novartis AG (NVS) was upgraded to B from B- on 2/2/2016 due to an increase in the dividend index, solvency index and valuation index. The quick ratio increased from 0.51 to 0.66, and debt to equity declined from 0.3 to 0.28.
B
Buy
1/12/2016Downgrade
Novartis AG (NVS) was downgraded to B- from B on 1/12/2016 due to a decline in the total return index and solvency index.
Novartis AG (NVS) was downgraded to B- from B on 1/12/2016 due to a decline in the total return index and solvency index.
B
Buy
12/28/2015Upgraded
Novartis AG (NVS) was upgraded to B from B- on 12/28/2015 due to an increase in the total return index and valuation index.
Novartis AG (NVS) was upgraded to B from B- on 12/28/2015 due to an increase in the total return index and valuation index.
B
Buy
12/1/2015Downgrade
Novartis AG (NVS) was downgraded to B- from B on 12/1/2015 due to a noticeable decline in the volatility index, total return index and solvency index.
Novartis AG (NVS) was downgraded to B- from B on 12/1/2015 due to a noticeable decline in the volatility index, total return index and solvency index.
B
Buy
10/13/2015Downgrade
Novartis AG (NVS) was downgraded to B from B+ on 10/13/2015 due to a noticeable decline in the volatility index and solvency index.
Novartis AG (NVS) was downgraded to B from B+ on 10/13/2015 due to a noticeable decline in the volatility index and solvency index.
B
Buy
9/22/2015Downgrade
Novartis AG (NVS) was downgraded to B+ from A- on 9/22/2015 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.56 to 0.5.
Novartis AG (NVS) was downgraded to B+ from A- on 9/22/2015 due to a substantial decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.56 to 0.5.
A
Buy
4/24/2015Downgrade
Novartis AG (NVS) was downgraded to A- from A on 4/24/2015 due to a noticeable decline in the growth index, dividend index and efficiency index. Operating cash flow declined 67.26% from $5.21B to $1.7B, total revenue declined 10.85% from $13.66B to $12.17B, and EBIT declined 8.32% from $3.14B to $2.88B.
Novartis AG (NVS) was downgraded to A- from A on 4/24/2015 due to a noticeable decline in the growth index, dividend index and efficiency index. Operating cash flow declined 67.26% from $5.21B to $1.7B, total revenue declined 10.85% from $13.66B to $12.17B, and EBIT declined 8.32% from $3.14B to $2.88B.
A
Buy
4/15/2015Upgraded
Novartis AG (NVS) was upgraded to A from A- on 4/15/2015 due to an increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to A from A- on 4/15/2015 due to an increase in the total return index and volatility index.
A
Buy
3/16/2015Downgrade
Novartis AG (NVS) was downgraded to A- from A on 3/16/2015 due to a decline in the total return index and volatility index.
Novartis AG (NVS) was downgraded to A- from A on 3/16/2015 due to a decline in the total return index and volatility index.
A
Buy
2/27/2015Upgraded
Novartis AG (NVS) was upgraded to A from A- on 2/27/2015 due to a noticeable increase in the total return index, growth index and dividend index. Operating cash flow increased 29.77% from $4.01B to $5.21B, EBIT increased 14.04% from $2.75B to $3.14B, and total revenue increased 2.68% from $13.3B to $13.66B.
Novartis AG (NVS) was upgraded to A from A- on 2/27/2015 due to a noticeable increase in the total return index, growth index and dividend index. Operating cash flow increased 29.77% from $4.01B to $5.21B, EBIT increased 14.04% from $2.75B to $3.14B, and total revenue increased 2.68% from $13.3B to $13.66B.
A
Buy
1/20/2015Upgraded
Novartis AG (NVS) was upgraded to A- from B+ on 1/20/2015 due to an increase in the volatility index, solvency index and total return index.
Novartis AG (NVS) was upgraded to A- from B+ on 1/20/2015 due to an increase in the volatility index, solvency index and total return index.
B
Buy
12/17/2014Downgrade
Novartis AG (NVS) was downgraded to B+ from A- on 12/17/2014 due to a decline in the volatility index, solvency index and total return index.
Novartis AG (NVS) was downgraded to B+ from A- on 12/17/2014 due to a decline in the volatility index, solvency index and total return index.
A
Buy
11/28/2014Upgraded
Novartis AG (NVS) was upgraded to A- from B+ on 11/28/2014 due to an increase in the volatility index, total return index and growth index. Earnings per share increased from $1.0342 to $1.3061, and operating cash flow increased 20.05% from $3.34B to $4.01B.
Novartis AG (NVS) was upgraded to A- from B+ on 11/28/2014 due to an increase in the volatility index, total return index and growth index. Earnings per share increased from $1.0342 to $1.3061, and operating cash flow increased 20.05% from $3.34B to $4.01B.
B
Buy
4/25/2014Downgrade
Novartis AG (NVS) was downgraded to B+ from A- on 4/25/2014 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 0.24 to 0.3.
Novartis AG (NVS) was downgraded to B+ from A- on 4/25/2014 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 0.24 to 0.3.
A
Buy
4/14/2014Upgraded
Novartis AG (NVS) was upgraded to A- from B+ on 4/14/2014 due to an increase in the total return index and volatility index.
Novartis AG (NVS) was upgraded to A- from B+ on 4/14/2014 due to an increase in the total return index and volatility index.
NYSE
03/05/2025 4:00PM Eastern
Quotes delayed
